Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News InspireMD Inc NSPR

Healthcare Medical Instruments & Supplies
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet... see more

Recent & Breaking News (NDAQ:NSPR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

GlobeNewswire 1 day ago

InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 8, 2024

InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

GlobeNewswire November 4, 2024

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

GlobeNewswire October 15, 2024

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

GlobeNewswire October 7, 2024

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard(TM) Prime Carotid Stent System

GlobeNewswire September 16, 2024

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 6, 2024

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

GlobeNewswire August 5, 2024

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

GlobeNewswire July 30, 2024

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

GlobeNewswire July 1, 2024

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024  

GlobeNewswire May 28, 2024

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 14, 2024

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

GlobeNewswire May 7, 2024

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

GlobeNewswire March 26, 2024

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 6, 2024

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

GlobeNewswire February 28, 2024

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard(TM) Neuroprotection System

GlobeNewswire February 12, 2024

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

GlobeNewswire January 31, 2024